RT Journal Article
SR Electronic
A1 Cunningham, Muriel
T1 Neutral Results Obtained in the ELIXA Trial
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 28
SP 14
OP 14
DO 10.1177/1559897715611120
UL http://mdc.sagepub.com/content/15/28/14.2.abstract
AB ELIXA was a randomized, double-blind, placebo-controlled trial among patients with type 2 diabetes mellitus who had experienced a recent acute coronary syndrome event. Lixisenatide was not superior to placebo in the primary composite end point of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for unstable angina.